ANX-005

Tanruprubart demonstrated significant functional improvements in Guillain-Barré syndrome patients as early as one week after treatment, with patients 14 times more likely to show improved mobility versus placebo.

The FDA has approved a new pre-filled syringe formulation of efgartigimod (VYVGART Hytrulo) for self-injection in adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Annexon Inc. announced plans to present Phase III trial results for ANX005 in Guillain-Barré Syndrome, triggering a significant 50% stock surge in after-hours trading. The upcoming data presentation, scheduled for June 4, 2024, represents a crucial milestone in addressing this rare autoimmune disorder affecting the nervous system.

Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.

Annexon, Inc. (ANNX) has made significant progress in developing treatments for neuroinflammatory diseases, with recent announcements including the expansion of its board of directors, positive results from clinical trials, and participation in major healthcare conferences.